This story was generated by Automated Insights () using data from Zacks Investment Research. The stock has risen 43% in the last 12 months. The company said it expects revenue in the range of $620 million to $680 million for the fiscal first quarter.Įndo expects full-year earnings in the range of $1.80 to $2.30 per share, with revenue ranging from $2.55 billion to $2.79 billion.Įndo shares have increased 30% since the beginning of the year. Vertex’ Pharmaceuticals earnings per share estimates have increased to 15.31 from 13. Revenue was reported as $2.9 billion.įor the current quarter ending in April, Endo expects its per-share earnings to range from 40 cents to 50 cents. Endo International plc’s ENDP fourth-quarter earnings of 84 cents per share beat the Zacks Consensus. Six analysts surveyed by Zacks expected $653.8 million.įor the year, the company reported net income of $183.9 million, or 79 cents per share, swinging to a profit in the period. The health care company posted revenue of $760.2 million in the period, which also topped Street forecasts. DUBLIN (AP) Endo International PLC (ENDP) on Thursday reported fourth-quarter net income of 119.3 million, after reporting a loss in the same period a year earlier. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 50 cents per share. Over the past 12 months, Endo Pharmaceuticals generated 541.0 million cash while it booked net income of 244.0 million. The results topped Wall Street expectations. 546.7M Reporting Date Aug 09 Earnings per Share Move your mouse over a quarter or year to see how estimates have changed over time.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |